Stocks
Moderna Stock Surges on Positive Cancer Vaccine Trial Results
Moderna's (MRNA) stock surged 9.4% in afternoon trading after positive Phase 3 trial results for its personalized cancer vaccine, intismeran autogene, were announced.
The trial, which evaluated the vaccine alongside Merck's Keytruda in high-risk melanoma patients, has continued to drive momentum since the previous clinical study data was released.
This optimism is also fueled by recent upgrades from Wall Street analysts at Argus and Bank of America, as well as improved regulatory sentiment following the FDA approval of Moderna's updated 2026-2027 COVID-19 vaccines.
The company has also received a $2.6 billion convertible note offering to fund its ongoing oncology development.